- Lung cancer treatment is stage-driven: surgery for early stages (up to 3A), combined chemoradiotherapy for stage 3.
- Stage 1A: surgery alone; stage 2: surgery + adjuvant chemo (~5% survival gain).
- Over a third are diagnosed at stage 4 with metastases - focus shifts to control and supporting the body.
- Anti-inflammatory diet, NK-cell-activating mushroom polysaccharides, and high vitamin D3 are studied as supportive measures.
Lung cancer treatment depends on the stage and is chosen with regard to the patient's age, condition and comorbidities. Early stages (up to and including 3A) are treated with surgery, which may be followed by adjuvant chemotherapy and radiotherapy.

1. Early stages (1–2): the fight for removal
Here the main goal is surgical removal. Stage 1A: surgery is the "gold standard"; additional treatment (chemotherapy) is usually not needed, because the risk outweighs the benefit. Stage 1B: surgery, plus possible chemotherapy only if risk factors are present (such as tumour size). Stage 2: surgery plus adjuvant chemotherapy — here the additional treatment increases survival by about 5%, so it is recommended more often.
2. Locally advanced disease (stage 3): a combined attack
This is the most complex group, and treatment often resembles a chess game. Sometimes chemotherapy and radiotherapy are given first to shrink the tumour, and only then is surgery performed. In other cases surgery is not possible, so aggressive combined radiation and drug treatment is used.
3. Advanced lung cancer (stage 4)
More than a third of those diagnosed already have metastases — that is, stage 4 disease. Because of the advanced disease and metastases in the lungs, life expectancy falls. Statistically, many patients cannot be cured, so it is very important to help the body fight.
Nutrition as an anti-inflammatory shield
Cancer thrives in an inflammatory environment; your goal is to extinguish it. Eliminating sugar: cancer cells consume glucose 10–50 times faster than healthy cells, so reducing sugar "starves" the tumour. Anti-inflammatory fats: increase omega-3 (fatty fish, hemp oil), which helps prevent cancer cachexia (weight loss). Cruciferous vegetables: broccoli and cabbage contain sulforaphane, which helps the liver detoxify chemotherapy residues.
Immune-system "tuning"
At stage 4 the body is depleted. Additional measures can help it not give up. Medicinal mushrooms (lentinan): they do not treat cancer directly, but activate your immune cells (NK cells) to recognise and destroy cancer cells more effectively. It is important to choose a concentrated multi-extract formula. Vitamin D3: blood levels are often critically low in cancer patients; maintaining a high level (about 80–100 ng/ml) is critical for immunity. Emotional health and movement also matter.
Medicinal mushrooms are studied for activating NK cells to recognise cancer cells. A concentrated multi-extract formula is preferable, alongside high vitamin D3.
Lentinan AXT by Zenius Labs™ →In stages 1–2 the main goal is surgical removal. Stage 1A: surgery is the gold standard, usually without chemotherapy. Stage 1B: surgery plus chemotherapy only if risk factors are present. Stage 2: surgery plus adjuvant chemotherapy, which increases survival by about 5%.
Stage 3 is the most complex group. Sometimes chemotherapy and radiotherapy are given first to shrink the tumour before surgery; in other cases surgery is not possible and aggressive combined radiation and drug treatment is used.
More than a third of patients have metastases at diagnosis. Many cannot be cured, so treatment focuses on controlling the disease and helping the body — through anti-inflammatory nutrition, immune support and vitamin D.
Medicinal mushrooms (lentinan) do not treat cancer directly but are studied for activating NK cells to recognise and destroy cancer cells. A concentrated multi-extract formula such as Lentinan AXT by Zenius Labs™ is preferable, alongside maintaining high vitamin D3 levels.
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemothe…. PubMed
- Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected …. PubMed
- Association between time-to-treatment and outcomes in non-small cell lung can…. PubMed
- Efficacy and safety of first-line carboplatin-versus cisplatin-based chemothe…. PubMed
- Yin X et al. A meta-analysis of lentinan injection combined with chemotherapy in the treatment of nonsmall cell lung cancer. Indian journal of cancer. 2015. PubMed
- Zhao C et al. Lentinan combined with cisplatin for the treatment of non-small cell lung cancer. Medicine. 2021. PubMed
- Li M et al. Lentinan triggers oxidative stress-mediated anti-inflammatory responses in lung cancer cells. Molecular and cellular biochemistry. 2022. PubMed
- Gui Y et al. Oridonin improves the therapeutic effect of lentinan on lung cancer. Experimental and therapeutic medicine. 2021. PubMed
- Wang Y et al. Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis. Medicine. 2024. PubMed
- Song Z et al. Translational Nanotherapeutics Reprograms Immune Microenvironment in Malignant Pleural Effusion of Lung Adenocarcinoma. Advanced healthcare materials. 2021. PubMed
- Congcong Q et al. Evaluation of Efficacy and Safety for Lentinan in the Control of the Malignant Pleural Effusions via Intrapleural Injection. The American journal of the medical sciences. 2019. PubMed
- Ansell SM et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. The New England journal of medicine. 2015. PubMed
- Goodman A et al. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nature reviews. Clinical oncology. 2017. PubMed
- Zak J et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science (New York, N.Y.). 2024. PubMed
- Chen H et al. Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer. Cancer cell. 2025. PubMed
- Redin E et al. Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy. Cancer research. 2025. PubMed
- Tani M et al. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. European journal of clinical pharmacology. 1992. PubMed
- Hamano K et al. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. International journal of immunopharmacology. 1999. PubMed
- Mattiola I et al. The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. Nature immunology. 2019. PubMed
- Chandrakesan P et al. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Molecular cancer therapeutics. 2020. PubMed
- Fan TW et al. Polarization and β-Glucan Reprogram Immunomodulatory Metabolism in Human Macrophages and Ex Vivo in Human Lung Cancer Tissues. Journal of immunology (Baltimore, Md. : 1950). 2022. PubMed
- Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
- Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
- Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
- Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
- Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
- Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
- Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
- Wu C et al. [Astaxanthin inhibits proliferation and promotes apoptosis of A549 lung cancer cells via blocking JAK1/STAT3 pathway]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. 2016. PubMed
- Qian J et al. Molecular mechanisms underlying the beneficial effects of Astaxanthin on metabolic changes in lung cancer and diabetes mellitus: A dual pathophysiological perspective. International immunopharmacology. 2025. PubMed
- Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
- Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
- Wang T et al. Astaxanthin protected against the adverse effects induced by diesel exhaust particulate matter via improving membrane stability and anti-oxidative property. Journal of hazardous materials. 2023. PubMed
- Deng S et al. Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. Journal of experimental & clinical cancer research : CR. 2018. PubMed
- Deng S et al. Correction to: Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. Journal of experimental & clinical cancer research : CR. 2021. PubMed
- Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
- Zhang Y et al. Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China. Journal of cancer research and clinical oncology. 2018. PubMed
- Wang XE et al. Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients. Pathology oncology research : POR. 2020. PubMed
- Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
- Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
- Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
- Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed